BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
2 Verstockt B, Bressler B, Martinez-Lozano H, McGovern D, Silverberg MS. Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management? Gastroenterology 2022;162:1370-82. [PMID: 34995534 DOI: 10.1053/j.gastro.2021.12.246] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lucaciu LA, Ilieș M, Vesa ȘC, Seicean R, Din S, Iuga CA, Seicean A. Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. J Pers Med 2021;11:1130. [PMID: 34834482 DOI: 10.3390/jpm11111130] [Reference Citation Analysis]
4 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Reference Citation Analysis]
5 Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Danese S, D’haens G, Eckmann L, Faubion WA, Feagan BG, Jairath V, Ma C, Mcgovern D, Panes J, Sandborn WJ, Silverberg MS, Vermeire S; Alimentiv Translational Research Consortium (ATRC). Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00574-7] [Reference Citation Analysis]
6 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Reference Citation Analysis]
7 Thomas JP, Modos D, Korcsmaros T, Brooks-Warburton J. Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease. Front Genet 2021;12:760501. [PMID: 34745229 DOI: 10.3389/fgene.2021.760501] [Reference Citation Analysis]
8 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Reference Citation Analysis]
9 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]